| Metastatic Castration-Sensitive Prostate Carcinoma
Erleada vs Xtandi
Side-by-side clinical, coverage, and cost comparison for metastatic castration-sensitive prostate carcinoma.Deep comparison between: Erleada vs Xtandi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXtandi has a higher rate of injection site reactions vs Erleada based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xtandi but not Erleada, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Erleada
Xtandi
At A Glance
Oral
Once daily
Androgen receptor inhibitor
Oral
Once daily
Androgen receptor inhibitor
Indications
- Metastatic Castration-Sensitive Prostate Carcinoma
- Nonmetastatic Castration-Resistant Prostate Carcinoma
- Hormone refractory prostate cancer
- Metastatic Castration-Sensitive Prostate Carcinoma
- Nonmetastatic Castration-Sensitive Prostate Carcinoma
Dosing
Metastatic Castration-Sensitive Prostate Carcinoma, Nonmetastatic Castration-Resistant Prostate Carcinoma 240 mg orally once daily with or without food; concurrent GnRH analog or prior bilateral orchiectomy required; reduce to 120 mg once daily in severe hepatic impairment (Child-Pugh C).
Hormone refractory prostate cancer, Metastatic Castration-Sensitive Prostate Carcinoma 160 mg orally once daily until disease progression or unacceptable toxicity; concurrent GnRH analog or prior bilateral orchiectomy required.
Nonmetastatic Castration-Sensitive Prostate Carcinoma 160 mg orally once daily until disease progression or unacceptable toxicity; GnRH analog may be given with or without XTANDI.
Contraindications
—
—
Adverse Reactions
Most common (>=10%) fatigue, arthralgia, rash, decreased appetite, fall, weight decreased, hypertension, hot flush, diarrhea, fracture
Serious cerebrovascular and ischemic cardiovascular events, fracture, ILD/pneumonitis, severe cutaneous adverse reactions (SCARs)
Postmarketing ILD/pneumonitis, Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), DRESS, lichenoid eruption
Most common (>=10%) Musculoskeletal pain, fatigue, hot flush, constipation, decreased appetite, diarrhea, hypertension, hemorrhage, fall, fracture, headache
Serious Seizure, posterior reversible encephalopathy syndrome, hypersensitivity, ischemic heart disease, falls and fractures
Postmarketing Vomiting, dysphagia, hypersensitivity (edema of face, tongue, lip, or pharynx), posterior reversible encephalopathy syndrome, dysgeusia, rash, severe cutaneous adverse reactions (Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, DRESS, acute generalized exanthematous pustulosis)
Pharmacology
Androgen receptor (AR) inhibitor; apalutamide binds directly to the ligand-binding domain of the AR, inhibiting nuclear translocation, DNA binding, and AR-mediated transcription, leading to decreased tumor cell proliferation and increased apoptosis in prostate cancer models.
Enzalutamide is an androgen receptor inhibitor that competitively inhibits androgen binding to androgen receptors and consequently inhibits nuclear translocation of androgen receptors and their interaction with DNA; its major metabolite, N-desmethyl enzalutamide, exhibits similar in vitro activity.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Erleada
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Xtandi
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (12/12)
UnitedHealthcare
Erleada
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (8/8)
Xtandi
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (5/8)
Humana
Erleada
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Xtandi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Prostate Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Prostate Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ErleadaView full Erleada profile
XtandiView full Xtandi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.